IPG-ONDANSETRON 4 MG
ONDANSETRON (ONDANSETRON HYDROCHLORIDE) : 4 MG · DIN 02304597 · MARCAN PHARMACEUTICALS INC
Health Canada status: APPROVED
What is IPG-ONDANSETRON?
IPG-ONDANSETRON 4 MG contains ONDANSETRON (ONDANSETRON HYDROCHLORIDE) : 4 MG. It is listed in the Health Canada Drug Product Database under DIN 02304597, held by MARCAN PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 29-Feb-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IPG-ONDANSETRON used for?
Prevention of nausea and vomiting associated with emetogenic chemotherapy and radiotherapy; maintenance of anti-emesis after IV doses for highly emetogenic chemotherapy; prevention of post-op nausea.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02304597 |
|---|---|
| Brand name | IPG-ONDANSETRON |
| Generic / active ingredient | ONDANSETRON (ONDANSETRON HYDROCHLORIDE) : 4 MG |
| Manufacturer | MARCAN PHARMACEUTICALS INC |
| Strength | 4 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A04AA01 ONDANSETRON |
| AHFS class | 56:22.20 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 29-Feb-2016 |
How is it administered?
Adults: 8 mg 1-2h before chemo/radio, then 8 mg twice daily (chemo) or every 8h (radio) for up to 5 days. Post-op: 16 mg 1h before anesthesia. Max 8 mg/day in moderate/severe hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (section 11 is listed in TOC but text ends at section 9).
How is it supplied?
Tamper-evident polyethylene containers of 30 or 100 tablets; blister packs of 10 tablets.
Contraindications
Hypersensitivity to ondansetron or any component; concomitant use of apomorphine (due to reports of profound hypotension and loss of consciousness).
Warnings and precautions
QTc interval prolongation and Torsade de Pointes; myocardial ischemia and coronary artery spasm; Serotonin Syndrome; potential for harm to fetus; masks signs of intestinal obstruction.
Is ONDANSETRON in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A04AA01 ONDANSETRON. 59 of 135 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-ONDANSETRON | 4 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02478927 |
| ACCEL-ONDANSETRON | 8 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02478935 |
| ACCEL-ONDANSETRON ODT | 4 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | DIN 02535319 |
| ACCEL-ONDANSETRON ODT | 8 MG | TABLET (ORALLY DISINTEGRATING) | ACCEL PHARMA INC | MARKETED | DIN 02535327 |
| APO-ONDANSETRON | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02288184 |
| APO-ONDANSETRON | 4 MG / 5 ML | SOLUTION | APOTEX INC | MARKETED | DIN 02291967 |
| APO-ONDANSETRON | 8 MG | TABLET | APOTEX INC | MARKETED | DIN 02288192 |
| AURO-ONDANSETRON INJECTION | 2 MG | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02491524 |
| AURO-ONDANSETRON INJECTION | 2 MG | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02491532 |
| AURO-ONDANSETRON ODT | 4 MG | TABLET (ORALLY DISINTEGRATING) | AURO PHARMA INC | MARKETED | DIN 02511282 |
Who else supplies ONDANSETRON worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ONDANSETRON appears in 992 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.